Royal Philips Electronics and Pittsburgh-based biosimulation firm Immunetrics announced a joint development agreement to explore new approaches to the problem of infectious disease in critical care.
Under the development agreement, Philips Research and Immunetrics will study the combination of advanced bioinformatics and computer modeling to identify opportunities to reduce the incidence and improve the management of systemic infection.
In particular, the companies said that they will focus their efforts seek to develop new mechanisms for early and effective intervention of sepsis, a life-threatening, systemic inflammatory response to infection.
Philips currently owns a 29 percent stake in Immunetrics.
The partnership unites Philips’ patient monitoring segment and Immunetrics' strengths in the modeling and simulation of complex biological systems, the companies said.